##### Table of Contents

---



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



---



FORM 10-Q



|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|- | ----------------------------------------------------------------------------------------



For the quarterly period ended June 30, 2005



OR



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|- | -----------------------------------------------------------------------------------------



For the transition period from
 to
.



Commission File No. 1-11181



IRIS INTERNATIONAL, INC.

(Exact Name
of Registrant as Specified in Its Charter)



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Delaware                                                       |  | 94-2579751                          
|(State or Other Jurisdiction of Incorporation or Organization) |  | (I.R.S. Employer Identification No.)
|                                                               | 
|9172 Eton Avenue, Chatsworth, CA.                              |  | 91311                               
|(Address of principal executive offices)                       |  | (Zip Code)                          



(818) 709-1244

(Registrants Telephone Number, Including Area Code)



Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ̈



Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes x No ̈



The registrant had 17,022,396 shares of common stock issued and outstanding as of August 9, 2005.



---



---

##### Table of Contents

IRIS INTERNATIONAL, INC.



INDEX TO FORM 10-Q



|          |  |                                                                                                                       |  |     
|--------- |  | --------------------------------------------------------------------------------------------------------------------- |  | ----
|          |  |                                                                                                                       |  | Page
|PART I    |  | FINANCIAL INFORMATION                                                                                                 |  |     
|          |  |                                                                                                                      
|Item 1.   |  | Financial Statements                                                                                                  |  | 3   
|          |  |                                                                                                                      
|          |  | Consolidated Balance Sheet as of June 30, 2005 (unaudited) and December 31, 2004                                      |  | 3   
|          |  |                                                                                                                      
|          |  | Consolidated Statements of Operations for the three months ended June 30, 2005 and 2004 (unaudited)                   |  | 4   
|          |  |                                                                                                                      
|          |  | Consolidated Statements of Operations for the six months ended June 30, 2005 and 2004 (unaudited)                     |  | 5   
|          |  |                                                                                                                      
|          |  | Consolidated Statements of Cash Flows for the six months ended June 30, 2005 and 2004 (unaudited)                     |  | 6   
|          |  |                                                                                                                      
|          |  | Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2005 and 2004 (unaudited) |  | 7   
|          |  |                                                                                                                      
|          |  | Notes to Consolidated Financial Statements                                                                            |  | 8   
|          |  |                                                                                                                      
|Item 2.   |  | Managements Discussion and Analysis of Financial Condition and Results of Operations                                 |  | 18  
|          |  |                                                                                                                      
|Item 3.   |  | Quantitative and Qualitative Disclosures About Market Risk                                                            |  | 30  
|          |  |                                                                                                                      
|Item 4.   |  | Controls and Procedures                                                                                               |  | 30  
|          |  |                                                                                                                      
|PART II   |  | OTHER INFORMATION                                                                                                     |  |     
|          |  |                                                                                                                      
|Item 2.   |  | Unregistered Sales of Equity Securities and Use of Proceeds                                                           |  | 32  
|          |  |                                                                                                                      
|Item 6.   |  | Exhibits                                                                                                              |  | 33  
|          |  |                                                                                                                      
|Signature |  |                                                                                                                       |  | 34  



2



---

##### Table of Contents

PART I

FINANCIAL INFORMATION



|Item 1. | Financial Statements
|------- | --------------------



IRIS INTERNATIONAL, INC.

CONSOLIDATED BALANCE SHEETS



(in thousands)



|                                                                                                                      |  |               |         |   |                  |   |         |  
|--------------------------------------------------------------------------------------------------------------------- |  | ------------- | ------- | - | ---------------- | - | ------- | -
|                                                                                                                      |  | June 30, 2005 |         |   | December 31,2004 |  
|                                                                                                                      |  | (unaudited)   |         |   |                  |  
|Assets                                                                                                                |  |               |         |   |                  |   |         |  
|Current assets:                                                                                                       |  |               |         |   |                  |   |         |  
|Cash and cash equivalents                                                                                             |  | $             | 16,992  |   |                  | $ | 12,839  |  
|Accounts receivable, net of allowance for doubtful accounts and sales returns of $324 and $336                        |  |               | 10,765  |   |                  |   | 8,847   |  
|Inventories, net                                                                                                      |  |               | 7,541   |   |                  |   | 7,834   |  
|Prepaid expenses and other current assets                                                                             |  |               | 638     |   |                  |   | 381     |  
|Investment available for sale                                                                                         |  |               | 74      |   |                  |   | 198     |  
|Deferred tax asset                                                                                                    |  |               | 6,526   |   |                  |   | 3,650   |  
|                                                                                                                      |  |               |         |   |                  |   |         |  
|Total current assets                                                                                                  |  |               | 42,536  |   |                  |   | 33,749  |  
|Property and equipment, at cost, net                                                                                  |  |               | 3,702   |   |                  |   | 3,880   |  
|Goodwill                                                                                                              |  |               | 189     |   |                  |   | 189     |  
|Software development costs, net                                                                                       |  |               | 1,851   |   |                  |   | 1,930   |  
|Deferred tax asset                                                                                                    |  |               | 3,773   |   |                  |   | 5,665   |  
|Inventories  long term portion                                                                                       |  |               | 167     |   |                  |   | 290     |  
|Other assets                                                                                                          |  |               | 4,362   |   |                  |   | 2,433   |  
|                                                                                                                      |  |               |         |   |                  |   |         |  
|Total assets                                                                                                          |  | $             | 56,580  |   |                  | $ | 48,136  |  
|                                                                                                                      |  |               |         |   |                  |   |         |  
|Liabilities and Shareholders Equity                                                                                  |  |               |         |   |                  |   |         |  
|Current liabilities:                                                                                                  |  |               |         |   |                  |   |         |  
|Accounts payable                                                                                                      |  | $             | 4,077   |   |                  | $ | 4,258   |  
|Accrued expenses                                                                                                      |  |               | 3,550   |   |                  |   | 3,398   |  
|Deferred service contract revenue                                                                                     |  |               | 1,259   |   |                  |   | 1,134   |  
|                                                                                                                      |  |               |         |   |                  |   |         |  
|Total current liabilities                                                                                             |  |               | 8,886   |   |                  |   | 8,790   |  
|Deferred service contract revenue, long term                                                                          |  |               | 111     |   |                  |   | 173     |  
|                                                                                                                      |  |               |         |   |                  |   |         |  
|Total liabilities                                                                                                     |  |               | 8,997   |   |                  |   | 8,963   |  
|Commitments and contingencies                                                                                         |  |               |         |   |                  |   |         |  
|Shareholders equity:                                                                                                 |  |               |         |   |                  |   |         |  
|Common stock, $.01 par value  authorized: 50 million shares; issued and outstanding: 16,950 shares and 15,962 shares |  |               | 169     |   |                  |   | 159     |  
|Additional paid-in capital                                                                                            |  |               | 67,687  |   |                  |   | 61,972  |  
|Unearned compensation                                                                                                 |  |               | (249    | ) |                  |   | (125    | )
|Accumulated other comprehensive income (loss)                                                                         |  |               | (28     | ) |                  |   | 11      |  
|Accumulated deficit                                                                                                   |  |               | (19,996 | ) |                  |   | (22,844 | )
|                                                                                                                      |  |               |         |   |                  |   |         |  
|Total shareholders equity                                                                                            |  |               | 47,583  |   |                  |   | 39,173  |  
|                                                                                                                      |  |               |         |   |                  |   |         |  
|Total liabilities and shareholders equity                                                                            |  | $             | 56,580  |   |                  | $ | 48,136  |  
|                                                                                                                      |  |               |         |   |                  |   |         |  



The accompanying notes
are an integral part of these consolidated financial statements.



3



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS



(unaudited  in thousands)



|                                                      |  |                                    |        |   |      |   |        |  
|----------------------------------------------------- |  | ---------------------------------- | ------ | - | ---- | - | ------ | -
|                                                      |  | For the three months endedJune 30, |       
|                                                      |  | 2005                               |        |   | 2004 |  
|Sales of IVD instruments                              |  | $                                  | 7,479  |   |      | $ | 3,517  |  
|Sales of IVD consumables and service                  |  |                                    | 5,887  |   |      |   | 4,724  |  
|Sales of small laboratory devices and supplies        |  |                                    | 2,211  |   |      |   | 1,951  |  
|Royalty and license revenues                          |  |                                    |       |   |      |   | 133    |  
|                                                      |  |                                    |        |   |      |   |        |  
|Net revenues                                          |  |                                    | 15,577 |   |      |   | 10,325 |  
|                                                      |  |                                    |        |   |      |   |        |  
|Cost of goods - IVD instruments                       |  |                                    | 4,280  |   |      |   | 2,588  |  
|Cost of goods - IVD consumables and service           |  |                                    | 2,600  |   |      |   | 1,963  |  
|Cost of goods - small laboratory devices and supplies |  |                                    | 1,101  |   |      |   | 994    |  
|                                                      |  |                                    |        |   |      |   |        |  
|Cost of goods sold                                    |  |                                    | 7,981  |   |      |   | 5,545  |  
|                                                      |  |                                    |        |   |      |   |        |  
|Gross margin                                          |  |                                    | 7,596  |   |      |   | 4,780  |  
|                                                      |  |                                    |        |   |      |   |        |  
|Marketing and selling expenses                        |  |                                    | 2,476  |   |      |   | 1,741  |  
|General and administrative expenses                   |  |                                    | 1,649  |   |      |   | 1,221  |  
|Research and development, net                         |  |                                    | 958    |   |      |   | 967    |  
|                                                      |  |                                    |        |   |      |   |        |  
|Total operating expenses                              |  |                                    | 5,083  |   |      |   | 3,929  |  
|                                                      |  |                                    |        |   |      |   |        |  
|Operating income                                      |  |                                    | 2,513  |   |      |   | 851    |  
|Other income (expense):                               |  |                                    |        |   |      |   |        |  
|Interest income                                       |  |                                    | 123    |   |      |   | 21     |  
|Interest expense                                      |  |                                    | (7     | ) |      |   | (145   | )
|Other income                                          |  |                                    |       |   |      |   | 5      |  
|                                                      |  |                                    |        |   |      |   |        |  
|Income before income taxes                            |  |                                    | 2,629  |   |      |   | 731    |  
|Provision for income taxes                            |  |                                    | 1,052  |   |      |   | 292    |  
|                                                      |  |                                    |        |   |      |   |        |  
|Net income                                            |  | $                                  | 1,577  |   |      | $ | 439    |  
|                                                      |  |                                    |        |   |      |   |        |  
|Basic net income per share                            |  | $                                  | 0.09   |   |      | $ | 0.03   |  
|                                                      |  |                                    |        |   |      |   |        |  
|Diluted net income per share                          |  | $                                  | 0.09   |   |      | $ | 0.03   |  
|                                                      |  |                                    |        |   |      |   |        |  
|Basic - average shares outstanding                    |  |                                    | 16,636 |   |      |   | 14,134 |  
|                                                      |  |                                    |        |   |      |   |        |  
|Diluted  average shares outstanding                  |  |                                    | 18,471 |   |      |   | 15,809 |  
|                                                      |  |                                    |        |   |      |   |        |  



The accompanying notes
are an integral part of these consolidated financial statements.



4



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS



(unaudited  in thousands)



|                                                      |  |                                  |        |   |      |   |        |  
|----------------------------------------------------- |  | -------------------------------- | ------ | - | ---- | - | ------ | -
|                                                      |  | For the six months endedJune 30, |       
|                                                      |  | 2005                             |        |   | 2004 |  
|Sales of IVD instruments                              |  | $                                | 13,418 |   |      | $ | 6,060  |  
|Sales of IVD consumables and service                  |  |                                  | 11,586 |   |      |   | 9,396  |  
|Sales of small laboratory devices and supplies        |  |                                  | 4,537  |   |      |   | 3,925  |  
|Royalty and license revenues                          |  |                                  |       |   |      |   | 319    |  
|                                                      |  |                                  |        |   |      |   |        |  
|Net revenues                                          |  |                                  | 29,541 |   |      |   | 19,700 |  
|                                                      |  |                                  |        |   |      |   |        |  
|Cost of goods - IVD instruments                       |  |                                  | 7,873  |   |      |   | 4,452  |  
|Cost of goods - IVD consumables and service           |  |                                  | 4,915  |   |      |   | 3,763  |  
|Cost of goods - small laboratory devices and supplies |  |                                  | 2,263  |   |      |   | 2,001  |  
|                                                      |  |                                  |        |   |      |   |        |  
|Cost of goods sold                                    |  |                                  | 15,051 |   |      |   | 10,216 |  
|                                                      |  |                                  |        |   |      |   |        |  
|Gross margin                                          |  |                                  | 14,490 |   |      |   | 9,484  |  
|                                                      |  |                                  |        |   |      |   |        |  
|Marketing and selling expenses                        |  |                                  | 4,867  |   |      |   | 3,231  |  
|General and administrative expenses                   |  |                                  | 3,043  |   |      |   | 2,414  |  
|Research and development, net                         |  |                                  | 2,041  |   |      |   | 2,021  |  
|                                                      |  |                                  |        |   |      |   |        |  
|Total operating expenses                              |  |                                  | 9,951  |   |      |   | 7,666  |  
|                                                      |  |                                  |        |   |      |   |        |  
|Operating income                                      |  |                                  | 4,539  |   |      |   | 1,818  |  
|Other income (expense):                               |  |                                  |        |   |      |   |        |  
|Interest income                                       |  |                                  | 176    |   |      |   | 32     |  
|Interest expense                                      |  |                                  | (12    | ) |      |   | (235   | )
|Other (expense) income                                |  |                                  | 44     |   |      |   | (2     | )
|                                                      |  |                                  |        |   |      |   |        |  
|Income before income taxes                            |  |                                  | 4,747  |   |      |   | 1,613  |  
|Provision for income taxes                            |  |                                  | 1,899  |   |      |   | 645    |  
|                                                      |  |                                  |        |   |      |   |        |  
|Net income                                            |  | $                                | 2,848  |   |      | $ | 968    |  
|                                                      |  |                                  |        |   |      |   |        |  
|Basic net income per share                            |  |                                  | 0.17   |   |      |   | 0.07   |  
|                                                      |  |                                  |        |   |      |   |        |  
|Diluted net income per share                          |  | $                                | 0.16   |   |      | $ | 0.07   |  
|                                                      |  |                                  |        |   |      |   |        |  
|Basic - average shares outstanding                    |  |                                  | 16,424 |   |      |   | 13,093 |  
|                                                      |  |                                  |        |   |      |   |        |  
|Diluted  average shares outstanding                  |  |                                  | 17,968 |   |      |   | 14,701 |  
|                                                      |  |                                  |        |   |      |   |        |  



The accompanying notes
are an integral part of these consolidated financial statements.



5



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS



(unaudited  in thousands)



|                                                                                  |  |                                  |        |   |      |   |        |  
|--------------------------------------------------------------------------------- |  | -------------------------------- | ------ | - | ---- | - | ------ | -
|                                                                                  |  | For the six months endedJune, 30 |       
|                                                                                  |  | 2005                             |        |   | 2004 |  
|Cash flows from operating activities:                                             |  |                                  |        |   |      |   |        |  
|Net income                                                                        |  | $                                | 2,848  |   |      | $ | 968    |  
|Adjustments to reconcile net income to net cash provided by (used in) operations: |  |                                  |        |   |      |   | 5      |  
|Deferred taxes, net                                                               |  |                                  | (1,873 | ) |      |   | 645    |  
|Depreciation and amortization                                                     |  |                                  | 1,077  |   |      |   | 820    |  
|Common stock and stock option compensation                                        |  |                                  | (311   | ) |      |   | 57     |  
|Loss (gain) on sale of investment                                                 |  |                                  | (17    | ) |      |   | 7      |  
|Changes in operating assets and liabilities:                                      |  |                                  |        |   |      |   |        |  
|Accounts receivable                                                               |  |                                  | (1,918 | ) |      |   | (1,028 | )
|Deferred service contract revenue                                                 |  |                                  | 63     |   |      |   | (168   | )
|Inventories, net                                                                  |  |                                  | 416    |   |      |   | (15    | )
|Prepaid expenses and other current assets                                         |  |                                  | (257   | ) |      |   | (141   | )
|Other assets                                                                      |  |                                  | (1,977 | ) |      |   | (57    | )
|Accounts payable                                                                  |  |                                  | (161   | ) |      |   | (605   | )
|Accrued expenses                                                                  |  |                                  | 152    |   |      |   | (72    | )
|                                                                                  |  |                                  |        |   |      |   |        |  
|Net cash provided by operating activities                                         |  |                                  | 1,788  |   |      |   | 411    |  
|                                                                                  |  |                                  |        |   |      |   |        |  
|Cash flows from investing activities:                                             |  |                                  |        |   |      |   |        |  
|Acquisition of property and equipment                                             |  |                                  | (414   | ) |      |   | (495   | )
|Software development costs                                                        |  |                                  | (171   | ) |      |   | (31    | )
|Sale of investments held for sale                                                 |  |                                  | 102    |   |      |   | 197    |  
|                                                                                  |  |                                  |        |   |      |   |        |  
|Net cash used in investing activities                                             |  |                                  | (483   | ) |      |   | (329   | )
|                                                                                  |  |                                  |        |   |      |   |        |  
|Cash flows from financing activities:                                             |  |                                  |        |   |      |   |        |  
|Issuance of common stock for cash                                                 |  |                                  | 2,868  |   |      |   | 12,805 |  
|Borrowings under line of credit                                                   |  |                                  |       |   |      |   | 2,900  |  
|Repayments of line of credit                                                      |  |                                  |       |   |      |   | (5,800 | )
|Repayments of term loan                                                           |  |                                  |       |   |      |   | (1,079 | )
|Repayments of notes payable                                                       |  |                                  |       |   |      |   | (1,069 | )
|Payments of capital lease obligations                                             |  |                                  | (20    | ) |      |   | (28    | )
|                                                                                  |  |                                  |        |   |      |   |        |  
|Net cash provided by financing activities                                         |  |                                  | 2,848  |   |      |   | 7,729  |  
|                                                                                  |  |                                  |        |   |      |   |        |  
|Net increase in cash and cash equivalents                                         |  |                                  | 4,153  |   |      |   | 7,811  |  
|Cash and cash equivalents at beginning of period                                  |  |                                  | 12,839 |   |      |   | 2,444  |  
|                                                                                  |  |                                  |        |   |      |   |        |  
|Cash and cash equivalents at end of period                                        |  | $                                | 16,992 |   |      | $ | 10,255 |  
|                                                                                  |  |                                  |        |   |      |   |        |  
|Supplemental schedule of non-cash financing activities:                           |  |                                  |        |   |      |   |        |  
|Issuance of common stock and common stock warrants for services                   |  | $                                | 311    |   |      | $ | 128    |  
|Supplemental disclosure of cash flow information:                                 |  |                                  |        |   |      |   |        |  
|Cash paid for income taxes                                                        |  | $                                |        |   |      | $ | 46     |  
|Cash paid for interest                                                            |  | $                                | 12     |   |      | $ | 97     |  



The accompanying notes
are an integral part of these consolidated financial statements.



6



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME



(unaudited  in thousands)



|                                             |  |                                    |       |   |      |   |     |  
|-------------------------------------------- |  | ---------------------------------- | ----- | - | ---- | - | --- | -
|                                             |  | For the three months endedJune 30, |      
|                                             |  | 2005                               |       |   | 2004 |  
|Net income                                   |  | $                                  | 1,577 |   |      | $ | 439 |  
|Unrealized loss on investments, net of taxes |  |                                    | (28   | ) |      |   | (88 | )
|                                             |  |                                    |       |   |      |   |     |  
|Comprehensive income                         |  | $                                  | 1,549 |   |      | $ | 351 |  
|                                             |  |                                    |       |   |      |   |     |  



|                                                    |  |                                  |       |   |      |   |     |  
|--------------------------------------------------- |  | -------------------------------- | ----- | - | ---- | - | --- | -
|                                                    |  | For the six months endedJune 30, |      
|                                                    |  | 2005                             |       |   | 2004 |  
|Net income                                          |  | $                                | 2,848 |   |      | $ | 968 |  
|Unrealized gain (loss) on investments, net of taxes |  |                                  | (39   | ) |      |   | (58 | )
|                                                    |  |                                  |       |   |      |   |     |  
|Comprehensive income                                |  | $                                | 2,809 |   |      | $ | 910 |  
|                                                    |  |                                  |       |   |      |   |     |  



The accompanying notes
are an integral part of these consolidated financial statements.



7



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



|1. | Company History
|-- | ---------------



IRIS International, Inc., (IRIS or the Company) was incorporated in California in 1979 and reincorporated during 1987 in Delaware
under the name of International Remote Imaging Systems, Inc. The Company changed its name to IRIS International, Inc. in December 2003. The Company designs, develops, manufactures and markets in vitro diagnostic (IVD) equipment,
including IVD imaging systems based on patented and proprietary automated intelligent microscopy (AIM) technology, as well as special purpose centrifuges and other small instruments for automating microscopic procedures performed in
clinical laboratories. On April 27, 2005 the Company signed an agreement to acquire the assets of the urinalysis business segment of Quidel Corporation, which was completed on June 2, 2005. See Note 3.



|2. | Summary of Significant Accounting Policies
|-- | ------------------------------------------



Basis of Presentation of Unaudited Interim Financial Statements



In the opinion of management, the accompanying unaudited consolidated financial statements contain all normal recurring
adjustments necessary to present fairly the financial position of the Company as of June 30, 2005 and the results of its operations for the three and six month periods then ended. These consolidated financial statements should be read in conjunction
with the consolidated financial statements and notes included in the Companys latest annual report on Form 10-K. Interim results are not necessarily indicative of results for a full year.



Use of Estimates



The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the
United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting periods. The significant estimates in the preparation of the consolidated financial statements relate to the assessment of the carrying value of accounts receivables, inventories, purchased
intangibles, estimated provisions for warranty costs and deferred tax assets. Actual results could differ materially from those estimates.



Principles of Consolidation



The consolidated financial statements include the accounts of IRIS International, Inc. and its wholly owned subsidiaries. All inter-company accounts and
transactions have been eliminated in the consolidated financial statements.



Cash Equivalents and Short-Term Investments



Short-term investments principally include certificates of deposit with maturities greater than three months and less than one year. For purposes of the statement of cash flows, IRIS considers all highly liquid debt instruments purchased
with a remaining maturity of three months or less when purchased to be cash equivalents. IRIS places its cash and investments with high credit quality financial institutions. At times, these deposits may be in excess of the federally insured limit.



Accounts Receivable



IRIS sells predominantly to entities in the healthcare industry. IRIS grants
uncollateralized credit to its customers, primarily hospitals, clinical and research laboratories, and distributors. IRIS performs ongoing credit evaluations of its customers before granting uncollateralized credit. The Company does not have any
single customer that accounts for 10% or more of its consolidated revenues or 10% or more of its accounts receivable at the balance sheet date.



8



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



Accounts receivable are customer obligations due under normal trade terms. We sell our products to
distributors and customers in the health care industry. We perform credit evaluations of our customers financial condition and although we generally do not require collateral, letters of credit may be required from our customers in certain
circumstances.



Senior management reviews accounts receivable
on a monthly basis to determine if any receivables will potentially be uncollectible. We include any accounts receivable balances that are determined to be uncollectible, along with a general reserve, in our overall allowance for doubtful accounts.
After all attempts to collect a receivable have failed, the receivable is written off against the allowance. Based on the information available to us, we believe our allowance for doubtful accounts as of June 30, 2005 is adequate.



Inventories



Inventories are carried at the lower of cost or market on a first in, first out basis. Provision for potentially obsolete or
slow-moving inventory is made based on managements analysis of inventory levels and future sales forecasts. The Company currently has approximately $167,000 of non-current inventory relating to spare parts for its legacy instruments which are
no longer produced but which the Company will continue to support and provide maintenance repairs for our customers. Other inventory that is considered excess inventory is fully reserved by the Company.



Investment available for sale



Management classifies the investment in the common shares of Applied Imaging
Corporation (NASDAQ: AICX), as available for sale. Investments in securities available for sale are reported at fair value with unrealized holding gains and losses, net of tax, reported as a separate component of shareholders equity until
realized, or until management believes a permanent decline in value has occurred. Realized gains and losses are included in earnings.



Property and Equipment and Depreciation



Property and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation is generally computed using the straight-line
method over three to five years, the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of their useful life or the remaining term of the lease.



Goodwill



Goodwill is recorded at cost. The realizability of the goodwill is evaluated at least annually, or as events or circumstances indicate a possible
inability to recover the carrying amount. Such evaluation is based on various analyses, including cash flow and profitability projections. The analysis necessarily involves significant management judgment to evaluate the capacity of an acquired
business to perform within projections. At June 30, 2005, the Company evaluated its goodwill and determined that fair value had not decreased below carrying value and no adjustment to impair goodwill was necessary in accordance with Statement of
Financial Accounting Standards (SFAS) No. 142, Goodwill and Other Intangible Assets.



Software Development Costs



The Company capitalizes certain software development costs for new products and product enhancements once all planning, designing, coding and testing activities necessary to establish that the product can be produced to meet its design
specifications are completed, and concludes capitalization when the product is ready for general release. Research and development costs relating to software development are expensed as incurred. Amortization of capitalized software development
costs is provided on a product-by-product basis at the greater of the amount computed using (a) the ratio of current revenues for a product to the total of current and anticipated future revenues or (b) the straight-line



9



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



method over the remaining estimated economic life of the product up to five years. The Company capitalized $171,000 and $31,000 of software development costs
and recorded amortization of software development costs of $250,000 and $255,000 during the six months ended June 30, 2005 and 2004.



Long-Lived Assets



The Company identifies and records an impairment loss for long-lived assets whenever events or changes in circumstances result in the carrying amount of
the assets exceeding the sum of the expected future undiscounted cash flows associated with such assets. The measurement of the impairment losses recognized is based on the difference between the fair values and the carrying amounts of the assets.



Stock-Based Compensation



The Company has adopted the disclosure-only provisions of Statement on
Financial Accounting Standards (SFAS) No. 123, Accounting for Stock-Based Compensation, as amended by SFAS No. 148. SFAS No. 123 defines a fair value based method of accounting for an employee stock option. Fair value of the stock option
is determined considering factors such as the exercise price, the expected life of the option, the current price of the underlying stock and its volatility, expected dividends on the stock, and the risk-free interest rate for the expected term of
the option. Under the fair value based method, compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period. Pro forma disclosures for entities that elect to continue to measure
compensation cost under the intrinsic method provided by Accounting Principles Board Opinion No. 25 must include the effects of all awards granted. The Company accounts for stock-based awards to non-employees in accordance with SFAS No. 123 and EITF
96-18. An expense is recognized for common stock, warrants or options issued or re-priced, for services rendered by non-employees based on the estimated fair value of the security exchanged.



If compensation expense for the stock options had been determined using
fair value at the grant date for awards during 2005 and 2004, consistent with the provisions of SFAS No. 123, the Companys net income and income per share would have been reduced to the pro forma amounts indicated below:



|                                                                                                                                             |  |                                    |       |   |                                  |   |      |      |  |   |       |   |  |   |      |  
|-------------------------------------------------------------------------------------------------------------------------------------------- |  | ---------------------------------- | ----- | - | -------------------------------- | - | ---- | ---- |  | - | ----- | - |  | - | ---- | -
|                                                                                                                                             |  | For the three monthsended June 30, |       |   | For the six monthsended June 30, |  
|(in thousands)                                                                                                                               |  | 2005                               |       |   | 2004                             |   |      | 2005 |  |   | 2004  |  
|Net income as reported                                                                                                                       |  | $                                  | 1,577 |   |                                  | $ | 439  |      |  | $ | 2,848 |   |  | $ | 968  |  
|Add: Stock-based employee compensation expense included in reported income, net of related tax effects                                       |  |                                    | 109   |   |                                  |   | 20   |      |  |   | 187   |   |  |   | 34   |  
|Deduct: Total stock-based Employee compensation expense determined under fair value based methods for all awards, net of related tax
effects |  |                                    | (256  | ) |                                  |   | (147 | )    |  |   | (469  | ) |  |   | (454 | )
|                                                                                                                                             |  |                                    |       |   |                                  |   |      |      |  |   |       |   |  |   |      |  
|Net income pro forma                                                                                                                         |  | $                                  | 1,430 |   |                                  | $ | 312  |      |  | $ | 2,566 |   |  | $ | 548  |  
|                                                                                                                                             |  |                                    |       |   |                                  |   |      |      |  |   |       |   |  |   |      |  
|Income per diluted share as reported                                                                                                         |  | $                                  | 0.09  |   |                                  | $ | 0.03 |      |  | $ | 0.16  |   |  | $ | 0.07 |  
|                                                                                                                                             |  |                                    |       |   |                                  |   |      |      |  |   |       |   |  |   |      |  
|Income per diluted share pro forma                                                                                                           |  | $                                  | 0.08  |   |                                  | $ | 0.02 |      |  | $ | 0.14  |   |  | $ | 0.04 |  
|                                                                                                                                             |  |                                    |       |   |                                  |   |      |      |  |   |       |   |  |   |      |  



The pro forma
calculations above are for informational purposes only. Future calculations of the pro forma effects of stock options may vary significantly due to changes in the assumptions described above as well as future grants, and for forfeitures of stock
options.



10



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



Revenue Recognition



Revenues are derived from the sale of IVD instruments, sales of consumable supplies and services for its IVD systems as well as sales of small
laboratory devices and related supplies. Revenue is recognized once all of the following conditions have been met: a) an authorized purchase order has been received in writing with a fixed and determinable sales price, b) customer credit worthiness
has been established, and c) delivery of the product based on shipping terms. The majority of domestic IVD instrument sales generally require installation and training to be performed.



Revenue is recorded in accordance with the provisions of Emerging Issues Task Force (EITF) Statement No. 00-21 Revenue
Arrangements with Multiple Deliverables and Staff Accounting Bulletin (SAB) No. 104 Revenue Recognition in Financial Statements which generally requires revenue earned on product sales involving multiple-elements to be allocated to
each element based on the relative fair values of those elements. Multiple elements of the Companys domestic product sales and typically include IVD instruments and training. Training elements are valued based on hourly rates, which the
Company charges for these services when sold apart from hardware sales. Accordingly, IRIS allocates revenue to each element in a multiple-element arrangement based on the elements respective fair value, with the fair value determined by the
price charged when that element is sold and specifically defined in a quotation or contract.



IRIS recognizes revenues from the sale of instruments, consumables and small laboratory devices when title and risk of loss passes to the customers and revenues from service contracts are recognized ratably over the
term of the service period, which typically ranges from twelve to sixty months. Payments for service contracts are generally received in advance. Deferred revenue represents the revenues to be recognized over the remaining term of the service
contracts.



Warranties



IRIS records warranty expense, based on managements estimate of
expected cost, as an accrued liability at the time of sale.



Research and
Development Expenditures



Except for certain software
development costs capitalized as described above (see Software Development Costs), research and development expenditures are charged to operations as incurred. Net research and development expense includes total research and development costs
incurred, including costs incurred under research and development grants and contracts, less costs reimbursed under research and development contracts.



The Company, from time to time receives grants from agencies of the U.S. Government. We do not recognize any revenue from such grants since they are cost
reimbursement grants whereby the Company submits requests for reimbursement for certain costs incurred. There are no ongoing obligations or requirements with respect to the grants received, the Company retains ownership of any intellectual property
that results from the research and development and the U.S. Government receives a right to use the results of the research for government projects. The Company received cost reimbursements (government grants) of $829,000 and $401,000 during the six
months ended June 30, 2005 and 2004.



11



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



Income Taxes



IRIS accounts for income taxes in accordance with SFAS No. 109 Accounting for Income Taxes, which requires
recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on
the differences between the financial statement and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to
reduce deferred tax assets to the amount expected to be realized. Income tax expense represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.



Marketing Costs



All costs related to marketing and advertising are expensed at the time the advertising takes place.



Fair Value of Financial Instruments



The amount recorded for financial instruments in the Companys
consolidated financial statements approximates fair value as defined in SFAS No. 107, Disclosures about Fair Value of Financial Instruments. The fair value of short-term borrowings and notes payable described in Note 4 approximate their
carrying value due to the variable nature of the interest rates in these instruments.



Earnings Per Share



Basic earnings per share
are computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing net income by the weighted average number of common shares and common stock equivalents
outstanding, calculated on the treasury stock method for options and warrants. Common stock equivalents for the six months ended June 30, 2005 and 2004 include 2,076,000 and 3,077,000 from stock options and warrants.



Segment Reporting



The Company determines and discloses its segments in accordance with SFAS No. 131; Disclosures about Segments of an
Enterprise and Related Information, which uses a management approach for determining business segments. The management approach designates the internal organization that is used by management for making operating decisions and
assessing performance as the source of the Companys reportable segments. SFAS No. 131 also requires disclosures about products and services, geographic areas, and major customers. See Note 10  Segment and Geographic
Information.



Certain Risks and Uncertainties



Dependence on Instrument Sales: The Company derives most of its revenues
from the sale of the urinalysis analyzers, and related supplies and services. Relatively modest declines in unit sales or gross margins could have a material adverse effect on the Companys revenues and profits.



Reliance on Single Source Suppliers: Certain key components of our
instruments are manufactured according to our specifications or are available only from single suppliers.



12



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



|3. | Acquisition of German Subsidiary
|-- | --------------------------------



On June 2, 2005, we completed the acquisition of the assets (primarily technology and inventory) of the urinalysis business of Quidel Corporation.
Pursuant to the acquisition agreement, we paid $500,000 in cash and assumed approximately $34,000 in accrued liabilities. We also incurred approximately $243,000 in professional and other fees, the total acquisition cost amounting to $777,000.



The acquisition was accounted for as a purchase with the
purchase price allocated on a preliminary basis, subject to adjustment, to the fair value of the assets acquired. The preliminary allocation of the acquisition price resulted in an excess of the fair value of the assets acquired over the purchase
price and resulted in negative goodwill. The negative goodwill reduced the non-current assets to zero with the acquisition cost of $777,000 allocated to the fair value of the inventory acquired.



The following unaudited condensed consolidated pro forma statement of
operations data shows the results of our operations for the six months ended June 30, 2005 and 2004 as if recently completed business combinations had occurred at the beginning of each period presented:



|                                      |  |                           |        |      |   |       
|------------------------------------- |  | ------------------------- | ------ | ---- | - | ------
|                                      |  | Six months ended June 30,
|(in thousands, except per share data) |  | 2005                      |        | 2004
|Revenues                              |  | $                         | 30,113 |      | $ | 20,503
|Net income                            |  |                           | 2,308  |      |   | 340   
|Net income per share  diluted        |  |                           | 0.13   |      |   | 0.03  



These unaudited
condensed consolidated pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the acquisitions taken place as of the beginning of the respective periods or the
results of our future operations. Furthermore, the pro forma results do not give effect to all cost savings or incremental costs that may occur as a result of the integration and consolidation of the acquisitions.



|4. | Inventories
|-- | -----------



Inventories consist of the following:



|                                        |  |              |       |   |                  |   |       |  
|--------------------------------------- |  | ------------ | ----- | - | ---------------- | - | ----- | -
|(in thousands)                          |  | June 30,2005 |       |   | December 31,2004 |  
|Finished goods                          |  | $            | 2,628 |   |                  | $ | 2,642 |  
|Work-in-process                         |  |              | 549   |   |                  |   | 664   |  
|Raw materials, parts and sub-assemblies |  |              | 4,531 |   |                  |   | 4,818 |  
|                                        |  |              |       |   |                  |   |       |  
|                                        |  |              | 7,708 |   |                  |   | 8,124 |  
|Less non-current portion                |  |              | (167  | ) |                  |   | (290  | )
|                                        |  |              |       |   |                  |   |       |  
|Inventories  current portion           |  | $            | 7,541 |   |                  | $ | 7,834 |  
|                                        |  |              |       |   |                  |   |       |  



|5. | Bank Loan Agreement
|-- | -------------------



In April 2004, the Company used a portion of the proceeds it received from a private placement of common stock to retire all outstanding indebtedness to
its former bank and subordinated note holder. See Note 7.



13



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



In May 2004, the Company signed a new credit facility with a major bank. The credit facility consists
of a $6.5 million revolving line of credit for working capital and a $10.0 million line of credit for acquisitions and product opportunities. Borrowings under the revolving line of credit are limited to a percentage of eligible receivables and
inventory. The entire credit facility has variable interest rates, which will change from time to time based on changes to either the LIBOR rate or the lenders prime rate. As of June 30, 2005, there were no borrowings under the new credit
facility. The Company is subject to certain financial covenants under the credit facility with the bank and as of June 30, 2005, the Company was in compliance with such covenants.



|6. | Income Taxes
|-- | ------------



The income tax provision differs from the federal statutory rate due primarily to state income taxes and permanent differences between income reported for
financial statement and income tax purposes.



Realization of
deferred tax assets associated with net operating losses (NOL) and tax credit carry forward is dependent upon our being able to generate sufficient taxable income prior to their expiration. The Company believes that it is more likely
than not that the deferred tax assets will be realized through future taxable income or alternative tax strategies. However, the net deferred tax assets could be reduced in the near term if managements estimates of taxable income during the
carryforward period are not realized or are significantly reduced or alternative tax strategies are not available. The Company will continue to review the estimates of taxable income and will make adjustments to the valuation allowance, when
necessary.



Also, should the Company undergo an ownership
change as defined in Section 382 of the Internal Revenue Code, NOLs generated prior to the ownership change would be subject to an annual limitation. If this occurs, a valuation allowance may be necessary.



|7. | Capital Stock
|-- | -------------



Private Placement of Stock



On April 16, 2004, the Company signed an agreement with an investment bank for the private placement of 2,130,000 shares of the Companys common stock at a price of $5.85 per share (a 10% discount to market). In addition, each of the
investors received a 5-year warrant to purchase 3 additional shares of common stock for each 20 shares of common stock purchased in the offering. The agreement required the Company to file a registration statement within 30 days of closing and to
have the registration statement declared effective within 90 days of closing. In May 2004, the Company filed a registration statement, which was declared effective on May 21, 2004. The Company realized net proceeds (after deducting offering expense
of $1.0 million) of approximately $11.5 million. The Company used approximately $5.5 million of the net proceeds to retire all of its outstanding indebtedness to its former bank and subordinated note holder.



Stock and Stock Option Issuances



During the six months ended June 30, 2005, the Company (i) issued 987,000
shares of common stock from the exercise of options, warrants and shares issued under our Employee Stock Purchase Plan, (ii) issued options to purchase 131,000 shares of common stock and (iii) cancelled and forfeited options to purchase 22,000
shares of common stock. At June 30, 2005, options to purchase 1,775,000 shares of common stock were issued and still outstanding. Outstanding options will expire at various dates through the end of 2012. The exercise price for such options ranges
from $0.69 to $16.96 per share. At June 30, 2005, there were no shares of common stock available for the granting of future options under the Companys stock option plans. On July 29, 2005, our shareholders approved an additional 1,200,000
shares for the Companys 1998 Stock Option Plan.



14



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



Warrants



At June 30, 2005, there were outstanding and exercisable warrants to purchase 108,000 shares at a price of $7.80 per share.



|8. | Contingencies
|-- | -------------



Litigation



From time
to time, the Company is party to certain litigation arising in the normal course of business. Management believes that the resolution of such matters will not have a material adverse effect on our financial position, results of operations or cash
flows.



Guarantees



The Company enters into indemnification provisions under (i) agreements with
other companies in the ordinary course of business, typically with business partners, contractors, customers and landlords, and (ii) agreements with investors. Under such provisions the Company generally indemnifies and holds harmless the
indemnified party for losses suffered or incurred by the indemnified party as a result of the Companys activities or, in some cases, as a result of the indemnified partys activities under the agreement. Indemnification provisions often
include indemnifications relating to representations made by the Company with regard to intellectual property rights. Such indemnification provisions generally survive termination of the underlying agreement. In addition, in some cases, the Company
agrees to reimburse employees for certain expenses and to provide salary continuation. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. To date, the Company
has not incurred any material costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. Accordingly, the Company has no recorded
liabilities for these agreements as of June 30, 2005.



|9. | Royalty Income
|-- | --------------



A competitor previously developed several urine sediment analyzers under license agreements using the Companys technology. The Company received
royalties under the license of $0 and $319,000 for the six months ended June 30, 2005 and 2004.



|10. | Segment and Geographic Information
|--- | ----------------------------------



The Companys continuing operations are organized on the basis of products and related services, and under SFAS No. 131, the Company operates in two
segments: (1) IVD instruments and (2) small laboratory devices and related supplies.



The IVD instrument segment designs, develops, manufactures, markets and distributes IVD systems based on patented and proprietary AIM technology for automating microscopic procedures for urinalysis. The segment also
provides ongoing sales of supplies and services necessary for the operation of installed urinalysis workstations. In the United States, these products are sold through a direct sales force. Internationally, products are sold through distributors.



The small laboratory devices segment designs, develops,
manufactures and markets a variety of benchtop centrifuges, small instruments and supplies. These products are used primarily for manual specimen preparation and dedicated applications in coagulation, cytology, hematology and urinalysis. These
products are sold worldwide through distributors.



15



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



The tables below present information about reported segments (in thousands):



|                                         |  |                |        |                        |   |                              |  |   |        |   |  |   |       
|---------------------------------------- |  | -------------- | ------ | ---------------------- | - | ---------------------------- |  | - | ------ | - |  | - | ------
|(in thousands)                           |  | IVDInstruments |        | SmallLaboratoryDevices |   | UnallocatedCorporateExpenses |  |   | Total 
|For the three months ended June 30, 2005 |  |                |        |                        |   |                              |  |   |        |   |  |   |       
|Revenues                                 |  | $              | 13,366 |                        | $ | 2,211                        |  | $ |       |   |  | $ | 15,577
|Interest income                          |  | $              | 121    |                        | $ | 2                            |  | $ |       |   |  | $ | 123   
|Interest expense                         |  | $              | 4      |                        | $ |                             |  | $ | 3      |   |  | $ | 7     
|Depreciation and amortization*           |  | $              | 450    |                        | $ | 34                           |  | $ | 22     |   |  | $ | 506   
|Segment pre tax profit                   |  | $              | 3,074  |                        | $ | 419                          |  | $ | (864   | ) |  | $ | 2,629 
|Segment assets                           |  | $              | 44,286 |                        | $ | 12,294                       |  | $ |       |   |  | $ | 56,580
|Investment in long-lived assets          |  | $              | 9,839  |                        | $ | 216                          |  | $ |       |   |  | $ | 10,055
|For the three months ended June 30, 2004 |  |                |        |                        |   |                              |  |   |        |   |  |   |       
|Revenues                                 |  | $              | 8,374  |                        | $ | 1,951                        |  | $ |       |   |  | $ | 10,325
|Interest income                          |  | $              | 20     |                        | $ | 1                            |  | $ |       |   |  | $ | 21    
|Interest expense                         |  | $              | 1      |                        | $ |                             |  | $ | 144    |   |  | $ | 145   
|Depreciation and amortization*           |  | $              | 408    |                        | $ | 34                           |  | $ | 17     |   |  | $ | 459   
|Other non-cash items                     |  | $              |       |                        |   |                             |  |   | 82     |   |  | $ | 82    
|Segment pre tax profit                   |  | $              | 1,147  |                        | $ | 349                          |  | $ | (765   | ) |  | $ | 731   
|Segment assets                           |  | $              | 29,461 |                        | $ | 2,799                        |  | $ | 8,187  |   |  | $ | 40,447
|Investment in long-lived assets          |  | $              | 159    |                        | $ | 15                           |  | $ |       |   |  | $ | 174   
|For the six months ended June 30, 2005   |  |                |        |                        |   |                              |  |   |        |   |  |   |       
|Revenues                                 |  | $              | 25,004 |                        | $ | 4,537                        |  | $ |       |   |  | $ | 29,541
|Interest income                          |  | $              | 172    |                        | $ | 4                            |  | $ |       |   |  | $ | 176   
|Interest expense                         |  | $              | 6      |                        | $ |                             |  | $ | 6      |   |  | $ | 12    
|Depreciation and amortization*           |  | $              | 940    |                        | $ | 93                           |  | $ | 44     |   |  | $ | 1,077 
|Segment profit                           |  | $              | 5,445  |                        | $ | 928                          |  | $ | (1,626 | ) |  | $ | 4,747 
|Segment assets                           |  | $              | 44,286 |                        | $ | 12,294                       |  | $ |       |   |  | $ | 56,580
|Investment in long-lived assets          |  | $              | 9,839  |                        | $ | 216                          |  | $ |       |   |  | $ | 10,055
|For the six months ended June 30, 2004   |  |                |        |                        |   |                              |  |   |        |   |  |   |       
|Revenues                                 |  | $              | 15,775 |                        | $ | 3,925                        |  | $ |       |   |  | $ | 19,700
|Interest income                          |  | $              | 31     |                        | $ | 1                            |  | $ |       |   |  | $ | 32    
|Interest expense                         |  | $              | 3      |                        | $ |                             |  | $ | 232    |   |  | $ | 235   
|Depreciation and amortization*           |  | $              | 775    |                        | $ | 72                           |  | $ | 29     |   |  | $ | 876   
|Other non-cash items                     |  | $              | 7      |                        |   |                             |  |   |       |   |  | $ | 7     
|Segment profit                           |  | $              | 2,325  |                        | $ | 766                          |  | $ | (1,478 | ) |  | $ | 1,613 
|Segment assets                           |  | $              | 29,799 |                        | $ | 10,648                       |  | $ |       |   |  | $ | 40,447
|Investment in long-lived assets          |  | $              | 489    |                        | $ | 37                           |  | $ |       |   |  | $ | 526   



|* | Included in depreciation and amortization above is amortization of deferred compensation in the amounts $79,000 and $34,000 for the three months ended June 30, 2005 and 2004; and
$187,000 and $57,000 for the six months ended June 30, 2005 and 2004.
|- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



16



---

##### Table of Contents

IRIS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS



The Company ships products from two locations in the United States. Substantially all long-lived
assets were located in the United States and totaled $10.3 million at June 30, 2005. Sales to international customers amounted to approximately $8.1 million and $3.1 million during the six months ended June 30, 2005 and 2004. Long-lived assets
include property and equipment, goodwill, software development costs, long-term portion of inventory and other long-term assets. Deferred income tax is excluded from long-lived assets.



17



---

##### Table of Contents

|Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations
|------- | -------------------------------------------------------------------------------------



Forward-Looking Statements



This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views about future events and financial results. We have
made these statements in reliance on the safe harbor created by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include our views on future financial results, financing sources, product development, capital
requirements, market growth and the like, and are generally identified by phrases such as anticipates, believes, estimates, expects, intends, plans and similar words.
Forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors which could cause the actual results to differ materially from the forward-looking statement. These uncertainties and other factors
include, among other things:



| |  |  | unexpected technical and marketing difficulties inherent in major product development efforts such as the new platform for our urinalysis workstation,
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the potential need for changes in our long-term strategy in response to future developments,
| | - |  | --------------------------------------------------------------------------------------------



| |  |  | future advances in diagnostic testing methods and procedures, as well as potential changes in government regulations and healthcare policies, both of which could adversely affect
the economics of the diagnostic testing procedures automated by our products,
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | rapid technological change in the microelectronics and software industries, and
| | - |  | -------------------------------------------------------------------------------



| |  |  | increasing competition from imaging and non-imaging based in vitrodiagnostic products.
| | - |  | --------------------------------------------------------------------------------------



Set forth below are other significant uncertainties and factors affecting forward-looking statements. The readers should
understand that uncertainties and other factors identified in this Quarterly Report are not a comprehensive list of all the uncertainties and other factors that may affect forward-looking statements. We do not undertake any obligation to update or
revise any forward-looking statements or the list of uncertainties and other factors that could affect those statements.



Overview



IRIS International, Inc. was incorporated in 1979. Our company consists of three operating units. Our largest unit, Iris Diagnostics Division, designs,
manufactures and markets in vitro diagnostics (IVD) systems, consumables and supplies for urinalysis. Our StatSpin subsidiary markets small centrifuges and other processing equipment and accessories for rapid specimen processing, and our Advanced
Digital Imaging and Research LLC (ADIR) subsidiary assists in the advancement of proprietary imaging technology while conducting government-sponsored research and contract development in imaging and pattern recognition.



We generate revenues primarily from three sources: Sales of; IVD instruments,
IVD consumables and service, and small laboratory device instruments and supplies. Sales of IVD consumables supplies and services currently represent approximately 40% of our revenues and contribute higher gross margins than other sources of
revenues. Consumables include products such as chemical reagents and urine test strips. Service revenues are derived primarily from annual service contracts purchased by our domestic customers after the initial year of sale, which is covered by
product warranties. Once our analyzers and systems are installed, we generate recurring revenue from sales of consumables. Consumable and service revenue will continue to expand as the installed base of related instruments expand. Sales of small
laboratory devices and supplies primarily consist of centrifuge systems and related supplies sold by StatSpin. Sales of StatSpins products are made worldwide through distributors.



Sales of IVD analyzers, consumables and services are made both domestically and internationally. Domestic sales are made
directly by our own sales staff to the customer, whereas international sales are made to independent distributors. International sales represent 31% of consolidated net revenues in the second quarter of 2005, compared to 17% during the comparable
quarter in 2004. With the launch of the iQ200 analyzer, we have increased our focus on the international marketplace, with the ultimate goal of balancing our urinalysis business between domestic and international markets. Since international sales
are made through



18



---

##### Table of Contents

independent distributors, gross profit margins are lower than domestic sales of the same products but without significant sales and marketing costs.



We make significant investments in research and development
for new products and enhancements to existing products. We internally fund our research and development programs, and through our subsidiary ADIR; we also receive government grants to fund various research activities.



The following table summarizes product technology expenditures for the
periods indicated:



|                                                                                                                            |      |                                    |       |      |                                  |   |       |   |  |      |       |   |  |   |       |  
|--------------------------------------------------------------------------------------------------------------------------- | ---- | ---------------------------------- | ----- | ---- | -------------------------------- | - | ----- | - |  | ---- | ----- | - |  | - | ----- | -
|(in thousands)                                                                                                              |      | For the three months endedJune 30, |       |      | For the six months endedJune 30, |  
|                                                                                                                            | 2005 |                                    |       | 2004 |                                  |   | 2005  |   |  | 2004 |      
|Total product technology expenditures                                                                                       |      | $                                  | 1,553 |      |                                  | $ | 1,280 |   |  | $    | 3,041 |   |  | $ | 2,452 |  
|Less: amounts capitalized during year to software development costs as reported in the consolidated statements of cash flow |      |                                    | (171  | )    |                                  |   | (17   | ) |  |      | (171  | ) |  |   | (31   | )
|Less: amounts reimbursed through grants for government sponsored research and development                                   |      |                                    | (424  | )    |                                  |   | (296  | ) |  |      | (829  | ) |  |   | (400  | )
|                                                                                                                            |      |                                    |       |      |                                  |   |       |   |  |      |       |   |  |   |       |  
|Research and development expense as reported in the consolidated statements of operations                                   |      | $                                  | 958   |      |                                  | $ | 967   |   |  | $    | 2,041 |   |  | $ | 2,021 |  
|                                                                                                                            |      |                                    |       |      |                                  |   |       |   |  |      |       |   |  |   |       |  



Critical Accounting Policies



Our consolidated financial statements are prepared in
accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.



Our significant accounting policies are described in Note 2 of the notes to
our consolidated financial statements, and of those policies, we believe that the following accounting policies involve the greatest degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in
fully understanding and evaluating our financial condition and results of operations.



Revenue recognition We derive our revenues from the sale of IVD instruments, consumable supplies and services for IVD systems and small laboratory devices and related supplies. Revenue is
recognized once all of the following conditions have been met: i) an authorized purchase order has been received in writing with a fixed and determinable sales price, ii) customer credit worthiness has been established, and iii) delivery of the
product based on shipping terms. The majority of domestic IVD instrument sales generally require that we install the instrument at our customers facility and train personnel in the instruments use.



Revenue is recorded in accordance with the provisions of Emerging Issues Task
Force (EITF) Statement 00-21 Revenue Arrangements with Multiple Deliverables and Staff Accounting Bulletin (SAB) 104 Revenue Recognition in Financial Statements which generally requires revenue earned on product sales involving
multiple-elements to be allocated to each element based on the relative fair values of those elements. Multiple elements of our domestic product sales include IVD instruments and training. Training elements are valued based on hourly rates, which we
charge for these services when sold apart from hardware sales.



Accordingly, we allocate revenue to each element in a multiple-element arrangement based on the elements respective fair value, with the fair value determined by the price charged when that element is sold and specifically defined in
a quotation or contract.



19



---

##### Table of Contents

We recognize revenues from service contracts ratably over the term of the service period, which typically
ranges from twelve to sixty months. Payments for service contracts are generally received in advance. Deferred revenue represents the revenues to be recognized over the remaining term of the service contracts.



Inventory valuation We value inventories at the lower of
cost or market value on a first-in, first-out basis. Provision for potentially obsolete or slow-moving inventory is made based on managements analysis of inventory levels and future sales forecasts. We recognize that although we have
introduced our new iQ200 product family of analyzers, an installed base of our legacy products still exists. We maintain a base supply of service parts for these products, a portion of which is classified as a long-term asset on our balance sheet.
Management will periodically review the carrying value of such parts to ensure that they continue to have net realizable value.



Capitalized Software We capitalize software development costs in connection with our development of our urine analyzers in accordance with
Statement of Financial Accounting Standards (SFAS) No. 86, Accounting for the Cost of Capitalized Software to Be Sold, Leased or Otherwise Marketed. We capitalize software development costs once technological feasibility is
established and such costs are determined to be recoverable against future revenues.



Capitalized software development costs are expensed to cost of sales over periods up to five years. When, in managements estimate, future revenues will not be sufficient to recover previously capitalized
software development costs, we will expense such items as additional software development amortization in the period the impairment is identified. Such adjustments are normally attributable to changes in market conditions or product quality
considerations.



Income taxes  We account
for income taxes in accordance with SFAS No. 109 Accounting for Income Taxes, which requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial
statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the differences between the financial statement and the tax bases of assets and liabilities using enacted tax rates in effect for the year in
which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense represents the tax payable for the period and the change
during the period in deferred tax assets and liabilities.



20



---

##### Table of Contents

Results of Operations



The following table summarizes results of operations data for the periods indicated. The percentages in the table are based on total revenues with the
exception of percentages for cost of goods sold that are computed on related revenue.



|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|------------------------------------- |  | -------------------------- | ------ |  | ------------------------ | - | ---- | - | ------ |  | --- | ---- |  | ------ |  | --- | ---- |  | ------ |  | --- | -
|                                      |  | Three months endedJune 30, |        |  | Six months endedJune 30, |  
|                                      |  | 2005                       |        |  |                          |   | 2004 |   |        |  |     | 2005 |  |        |  |     | 2004 |  |        | 
|Revenues                              |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|IVD instruments                       |  | $                          | 7,479  |  | 48                       | % |      | $ | 3,517  |  | 34  | %    |  | 13,418 |  | 46  | %    |  | 6,060  |  | 31  | %
|IVD consumables and service           |  |                            | 5,887  |  | 38                       | % |      |   | 4,724  |  | 46  | %    |  | 11,586 |  | 39  | %    |  | 9,396  |  | 48  | %
|Small laboratory devices and supplies |  |                            | 2,211  |  | 14                       | % |      |   | 1,951  |  | 19  | %    |  | 4,537  |  | 15  | %    |  | 3,925  |  | 20  | %
|Royalty and license revenues          |  |                            |       |  |                          |   |      |   | 133    |  | 1   | %    |  |       |  |     |      |  | 319    |  | 1   | %
|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|Total revenues                        |  |                            | 15,577 |  | 100                      | % |      |   | 10,325 |  | 100 | %    |  | 29,541 |  | 100 | %    |  | 19,700 |  | 100 | %
|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|Cost of Goods Sold                    |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|IVD instruments                       |  |                            | 4,280  |  | 57                       | % |      |   | 2,588  |  | 74  | %    |  | 7,873  |  | 59  | %    |  | 4,452  |  | 73  | %
|IVD consumable and supplies           |  |                            | 2,600  |  | 44                       | % |      |   | 1,963  |  | 42  | %    |  | 4,915  |  | 42  | %    |  | 3,763  |  | 40  | %
|Small laboratory devices and supplies |  |                            | 1,101  |  | 50                       | % |      |   | 994    |  | 51  | %    |  | 2,263  |  | 50  | %    |  | 2,001  |  | 51  | %
|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|Total costs                           |  |                            | 7,981  |  | 51                       | % |      |   | 5,545  |  | 54  | %    |  | 15,051 |  | 51  | %    |  | 10,216 |  | 52  | %
|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|Gross margin                          |  |                            | 7,596  |  | 49                       | % |      |   | 4,780  |  | 46  | %    |  | 14,490 |  | 49  | %    |  | 9,484  |  | 48  | %
|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|Operating expenses                    |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|Marketing and selling                 |  |                            | 2,476  |  | 16                       | % |      |   | 1,741  |  | 17  | %    |  | 4,867  |  | 16  | %    |  | 3,231  |  | 16  | %
|General and administrative            |  |                            | 1,649  |  | 11                       | % |      |   | 1,221  |  | 12  | %    |  | 3,043  |  | 10  | %    |  | 2,414  |  | 12  | %
|Research and development, net         |  |                            | 958    |  | 6                        | % |      |   | 967    |  | 9   | %    |  | 2,041  |  | 7   | %    |  | 2,021  |  | 10  | %
|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|Total operating expenses              |  |                            | 5,083  |  | 33                       | % |      |   | 3,929  |  | 38  | %    |  | 9,951  |  | 34  | %    |  | 7,666  |  | 39  | %
|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|Operating income                      |  |                            | 2,513  |  | 16                       | % |      |   | 851    |  | 8   | %    |  | 4,539  |  | 15  | %    |  | 1,818  |  | 9   | %
|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  
|Net income                            |  | $                          | 1,577  |  | 10                       | % |      | $ | 439    |  | 4   | %    |  | 2,848  |  | 10  | %    |  | 968    |  | 5   | %
|                                      |  |                            |        |  |                          |   |      |   |        |  |     |      |  |        |  |     |      |  |        |  |     |  



Comparison of the three months
ended June 30, 2005 to 2004



Net revenues for the three
months ended June 30, 2005 increased 51% over the prior year quarter. Revenues from the IVD urinalysis segment totaled $13.4 million in the current quarter, up from $8.4 million in the prior year quarter. Sales of IVD instruments increased to $7.5
million from $3.5 million, a 113% increase over the prior year quarter. The increase in instrument sales is due to continued strong unit sales of 124 iQ200 analyzers and systems during the current quarter as compared to unit sales of 52 iQ200
analyzers and systems during the prior year quarter. Sales of IVD consumables and service increased to $5.9 million from $4.7 million, an increase of $1.2 million or 25%, primarily due to the larger installed base of instruments. Revenues from the
small laboratory devices segment increased to $2.2 million from $2.0 million, or 13%. This increase is primarily due to increased unit sales of centrifuges, parts and service within this segment.



Consolidated gross profit margins improved to 49% of revenues as compared to
47% during the prior year quarter. For the IVD instruments, margins improved to 43% of related revenues as compared to 26% for the prior year quarter. The improvement was attributable to the economies of scale that resulted from greater overhead
absorption and other efficiencies from higher production levels during the quarter. Margins on IVD consumables and service were lower during the current quarter, primarily as a result of higher sales to international independent distributors at
lower margins as well as the fact that our instruments include a one-year warranty which reduces service related revenues. Margins on our small laboratory devices and supplies were 1% higher during the current quarter due to increased volume and
product mix.



21



---

##### Table of Contents

Marketing and selling expenses totaled $2.5 million for the three months ended June 30, 2005 as compared
to $1.7 million in the prior year quarter, a 42% increase. As a percentage of sales such expenses during the current quarter were 16% of revenues compared to 17% during the prior year quarter. During the current quarter we incurred additional sales
and marketing personnel costs of approximately $330,000 and $100,000 of additional travel costs to support the increased sales revenues during the quarter.



General and administrative expenses increased in the quarter to $1.6 million from $1.2 million in the prior year quarter. The increase includes
approximately $100,000 of increased professional fees and the remainder relates to additional personnel costs during the quarter. As a percentage of sales, general and administrative expenses were 11% during the current quarter as compared to 12%
for the prior year quarter.



Net research and development
expense as shown in the accompanying statements of operations amounted to $1.0 million during both periods. Research and Development expenses were net of reimbursed costs received from governmental research and development grants, which amounted to
$424,000 and $227,000 during the three months ended June 30, 2005 and 2004. We expect to continue investing in research and development activities during the remainder of 2005 but at a slightly higher rate than the current quarter.



Interest income during the quarter amounted to $123,000, an increase from
$102,000 over the prior year quarter and relates primarily to our investment of excess funds during the quarter plus interest received on sales-type equipment leases. Interest expense during the current quarter decreased to $7,000, primarily
relating to facility fees on our unused line of credit, down from $145,000 in the prior year quarter as a result of the repayment of outstanding indebtedness in the second quarter of 2004.



During the second quarter of 2005 the income tax provision amounted to $1.1
million as compared to $292,000 during the prior year quarter. The tax provision continues to be a non-cash item, since we have significant deferred tax assets relating to tax loss carryforwards.



Comparison of the six months ended June 30, 2005 to 2004



Net revenues for the six months ended June 30, 2005 increased 50% over the
prior year period. Revenues from the IVD urinalysis segment totaled $25.0 million during the current year six month period, up from $15.8 million in the prior year period. Sales of IVD instruments increased to $13.4 million from $6.1 million, a 121%
increase over the prior year period. The increase in instrument sales is due to the strong sales of iQ200 analyzers and systems during the current year six month period as compared to the prior year period. Sales of IVD consumables and service
increased to $11.6 million up from $9.4 million, an increase of $2.2 million or 23%, primarily due to the larger installed base of instruments. Revenues from the small laboratory devices segment increased to $4.5 million from $3.9 million, or 16%.
This increase is primarily due to increased sales of centrifuges, parts and service within this segment.



Gross profit margins were slightly better during the current year as compared to the prior year period. For the IVD instruments, margins improved to 41%
of related revenues as compared to 27% for the prior year. The improvement was attributable to the economies of scale that resulted from greater overhead absorption and other efficiencies from higher production levels during the current year. Gross
margin on IVD consumables and service was lower during the current quarter, primarily as a result of higher sales to international independent distributors at lower margins as well as our instruments include a one-year warranty during which period
we dont realize service revenue but incur warranty cost. Margins on our small laboratory devices and supplies improved by 1% during the current year due to increased volume and product mix.



Marketing and selling expenses totaled $4.9 million for the six months ended
June 30, 2005 as compared to $3.2 million in the prior year six month period and as a percentage of sales such expenses were 16% during both periods. During the current quarter we incurred additional sales and marketing personnel costs of
approximately $651,000, additional travel costs to support the increased sales revenues during the period of approximately $178,000 and additional consulting fees of approximately $80,000.



General and administrative expenses increased to $3.0 million from $2.4
million during the prior year period. The increase includes approximately $257,000 of added personnel costs, $220,000 of increased professional fees, a portion of which are attributed to compliance with Section 404 of the Sarbanes Oxley Act of 2002,
and the remainder to various costs resulting from the increase revenues during the period.



22



---

##### Table of Contents

Net research and development expense as shown in the accompanying statements of operations amounted to
$2.0 million during both the current six month period and the prior year six month period. Research and Development expenses were net of reimbursed costs received from governmental research and development grants, which amounted to $829,000 and
$400,000 during the six months ended June 30, 2005 and 2004. We expect to continue investing in research and development activities during the remainder of 2005 but at a higher rate than the first half of the year.



Interest income during the six months ended June 30, 2005 amounted to
$176,000, an increase over $32,000 over the prior year and relates primarily to our investment of excess funds during the year plus interest received on sales-type equipment leases. Interest expense during the period decreased to $12,000
relating primarily to facility fees on our unused line of credit down from $235,000 in the prior year as a result of the repayment of outstanding indebtedness in the second quarter of 2004.



Off-Balance Sheet Arrangements



At June 30, 2005 and 2004, we did not have any relationships with
unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other
contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.



Liquidity and Capital Resources



Our primary source of liquidity is cash from operations, which depends heavily on sales of our IVD urinalysis systems and the sales of consumables and
service for these systems as well as the sale of small laboratory devices and supplies. During the first six months of 2005, our cash and cash equivalents increased to $17.0 million.



On June 2, 2005, we completed the acquisition of the assets of the urinalysis business of Quidel Corporation. Pursuant to
the acquisition agreement, we paid $500,000 in cash and assumed approximately $34,000 in accrued liabilities. We also incurred approximately $243,000 in professional and other fees, the total acquisition cost amounting to $777,000. We anticipate
investing additional funds in expanding this product line during the remainder of 2005.



Operating Cash Flows.Cash used in operations for the current year six month period amounted to $969,000 compared to cash provided by operations of $411,000 in the prior year. Cash used in operations for the
six months resulted primarily from increases in receivables ($1.9 million) due to increased sales during the period and increases in other assets ($2.0 million) due to additional sales-type leases financed internally. These uses of cash were
partially offset by net income in the current year ($2.8 million), a reduction in inventory ($416,000) due to greater than anticipated sales during the period, and non-cash items consisting primarily of deferred taxes ($984,000) and depreciation and
amortization ($1.1 million).



The relationship of receivables
to revenues has improved to 59 days sales in accounts receivable as compared to 66 days sales in accounts receivable at the beginning of the year. Inventories during the current quarter decreased $416,000 since the beginning of the year with the
number of days sales in inventory decreasing to 94 days at the end of the first six months as compared to 128 days at the end of 2004. The improvement results from the increased sales during the first half of 2005 and improved inventory management.



Investing Activities.Cash used in investing activities
totaled $483,000 during the six months ended June 30, 2005 ($329,000 in 2004) for additions to property and equipment of $414,000 ($495,000 in 2004), capitalized software development costs of $171,000 ($31,000 in 2004) and partially offset by
proceeds from the sales of investments held for sale in the amounts of $102,000 ($197,000 in 2004).



23



---

##### Table of Contents

Financing Activities.For the six months ended June 30, 2005, financing activities provided $2.8
million of cash, compared to $7.7 million provided during the prior year. During the current year, we received $2.8 million from issuances of shares of common stock whereas in the prior year we received $12.8 million for issuances of our common
shares and $2.9 million in borrowings on our bank credit line partially offset by $7.9 million in repayments of indebtedness.



In May 2004, we signed a new credit facility with a major bank. The credit facility consists of a $6.5 million revolving line of credit for working
capital and a $10.0 million line of credit for acquisitions and product opportunities. Borrowings under the revolving line of credit are limited to a percentage of eligible receivables and inventory. The entire credit facility has variable interest
rates, which will change from time to time based on changes to either the LIBOR rate or the lenders prime rate. As of June 30, 2005, there were no borrowings under the new credit facility. We are subject to certain financial covenants under
the credit facility with the bank and as of June 30, 2005, we were in compliance with such covenants.



We believe that our current cash on hand, together with cash generated from operations and cash available under the credit facility with the bank will be
sufficient to fund normal operations. However additional funding may be required to fund expansion of our business. There is no assurance that such funding will be available, on terms acceptable to us.



New Accounting Pronouncements



In November 2004, the Financial Accounting Standards Board
(FASB) issued SFAS No. 151, Inventory Costs, an amendment of APB Opinion No. 43, Chapter 4. SFAS No. 151 clarifies the language used in Accounting Principles Board (APB) Opinion No. 43 with respect to accounting for
abnormal amounts of idle facility expenses, freight, handling costs and spoilage. The guidance does not result in a substantive change in accounting for these costs but eliminates inconsistencies in wording between U.S. and international accounting
standards. As such, this pronouncement is not expected to have any material impact on our consolidated statements of operations or financial position.



In December 2004, the Financial Accounting Standards Board, or FASB, issued SFAS No. 123 (Revised 2004), Share-Based Payment,or SFAS No. 123R,
which is a revision of SFAS No. 123. SFAS No. 123R supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and amends SFAS No. 95, Statement of Cash Flows. SFAS No. 123R requires all share-based payments to employees,
including grants of employee stock options, to be recognized in the income statement based on their fair values. SFAS No. 123R is effective for us beginning January 1, 2006 and will require us to expense share-based payments under the modified
prospective method. Under this method, compensation expense is recognized for all share-based payments granted after January 1, 2006 and also for all awards granted prior to January 1, 2006 that remain unvested on the effective date. We will
adopt SFAS No. 123R effective January 1, 2006 using the modified prospective method. Consequently, compensation expense for awards that we granted prior to January 1, 2006 that are not fully vested on January 1, 2006 will be subject to expense
beginning January 1, 2006 under SFAS No. 123R. We are currently evaluating the effects of adopting this standard on our results of operations or financial position.



Inflation



We do not foresee any material impact on our operations from inflation.



Healthcare Reform Policies



In recent years, an increasing number of legislative proposals have been introduced or proposed in Congress and in some state legislatures that would
effect major changes in the healthcare system, nationally, at the state level or both. Future legislation, regulation or payment policies of Medicare, Medicaid, private health insurance plans, health maintenance organizations and other third-party
payors could adversely affect the demand for our current or future products and our ability to sell our products on a profitable basis. Moreover, healthcare legislation is an area of extensive and dynamic change, and we cannot predict future
legislative changes in the healthcare field or their impact on our business.



24



---

##### Table of Contents

RISK FACTORS



Risks Related to Our Business



Our success depends largely on the acceptance of our new iQ200 operating platform.



Our current strategy assumes that our iQ200 operating platform will be
adopted by a large number of end-users. We have invested and continue to invest, a substantial amount of our resources in promotion and marketing of the iQ200 operating platform in order to increase its market penetration, expand its sales into new
geographic areas and enhance and expand its system features. A failure of our iQ200 operating platform to achieve and maintain a significant market presence, or the failure to successfully implement our promotion and marketing strategy, will have a
material adverse effect on our financial condition and results of operations.



Any failure to successfully introduce our future products and systems into the market could adversely affect our business.



The commercial success of our future products and systems depends upon their acceptance by the medical community. Our future
product plans include capital-intensive laboratory instruments. We believe that these products can significantly reduce labor costs, improve precision and offer other distinctive benefits to the medical research community. However, there is often
market resistance to products that require significant capital expenditures or which eliminate jobs through automation. We have no assurance that the market will accept our future products and systems, or that sales of our future products and
systems will grow at the rates expected by our management.



If we fail to meet changing demands of technology, we may not continue to be able to compete successfully with our competitors.



The market for our products and systems is characterized by rapid technological advances, changes in customer requirements, and frequent new product
introductions and enhancements. Our future success depends upon our ability to introduce new products that keep pace with technological developments, enhance current product lines and respond to evolving customer requirements. Our failure to meet
these demands could result in a loss of our market share and competitiveness and could harm our revenues and results of operations.



Any failure or inability to protect our technology and confidential information could adversely affect our business.



Patents.Our commercial success depends in part on our ability
to protect and maintain our Automated Intelligent Microscopy (or AIM) and other proprietary technology. We have received patents with respect to portions of the technologies of AIM. However, ownership of technology patents may not insulate us from
potentially damaging competition. Patent litigation relating to clinical laboratory instrumentation patents (like the ones we own) often involves complex legal and factual questions. Therefore, we can make no assurance that claims under patents
currently held by us, or our pending or future patent applications, will be sufficiently broad to adequately protect what we believe to be our proprietary rights. Additionally, one or more of our patents could be circumvented by a competitor. We
believe that our proprietary rights do not infringe upon the proprietary rights of third parties. However, third parties may assert infringement claims against us in the future. If we are unsuccessful in our defense against any infringement claim
our patents, or patents in which we have licensed rights, may be held invalid and unenforceable.



Trade Secrets.We have trade secrets, unpatented technology and proprietary knowledge related to the sale, promotion, operation, development
and manufacturing of our products. We generally enter into confidentiality agreements with our employees, suppliers and consultants. However, we cannot guarantee that our trade secrets, unpatented technology or proprietary knowledge will not become
known or be independently developed by competitors. If any of this proprietary information becomes known to third parties, we may have no practical recourse against these parties.



Copyrights and Trademarks.We claim copyrights in our software and the ways in which it assembles and displays
images. We also claim trademark rights in the United States and other foreign countries. However, we



25



---

##### Table of Contents

can make no assurance that we will be able to obtain enforceable copyright and trademark protection, nor that this protection will provide us a significant
commercial advantage.



Potential Litigation Expenses.Offensive or defensive litigation regarding patent and other intellectual property rights could be time-consuming and expensive. Additionally, litigation could demand significant attention from our technical and management personnel. Any
change in our ability to protect and maintain our proprietary rights could materially and adversely affect our financial condition and results of operations.



Our products could infringe on the intellectual property rights of others.



Given the complete factual and legal issues associated with intellectual property rights, there can be no assurance that our
current and future products do not or will not infringe the intellectual property rights of others. A determination that such infringement exists or even a claim that it exists could involve us in costly litigation and have an adverse effect on our
business and financial condition.



We operate in a
consolidating industry that creates barriers to our market penetration.



The healthcare industry in recent years has been characterized by consolidation. Large hospital chains and groups of affiliated hospitals prefer to negotiate comprehensive supply contracts for all of their supply
needs at once. Large suppliers can often equip an entire laboratory and offer hospital chains and groups one-stop shopping for laboratory instruments, supplies and service. Larger suppliers also typically offer annual rebates to their customers
based on the customers total volume of business with the supplier. The convenience and rebates offered by these large suppliers are administrative and financial incentives that we do not offer our customers. Our plans for further market
penetration in the urinalysis market will depend in part on our ability to overcome these and any new barriers resulting from continued consolidation in the healthcare industry. The failure to overcome such barriers could have a material adverse
effect on our financial condition or results of operation.



Since we operate in the medical technology industry, our products are subject to government regulation that could impair our operations.



Most of our products are subject to stringent government regulation in the United States and other countries. These regulatory processes can be
lengthy, expensive and uncertain. Additionally, securing necessary clearances or approvals may require the submission of extensive official data and other supporting information. Our failure to comply with applicable requirements could result in
fines, recall or seizure of products, total or partial suspension of production, withdrawal of existing product approvals or clearances, refusal to approve or clear new applications or notices, or criminal prosecution. If any of these events were to
occur, they could harm our business. Changes in existing federal, state or foreign laws or regulations, or in the interpretation or enforcement of these laws, could also materially and adversely affect our business.



Changes in government regulation of the healthcare industry could
adversely affect our business.



Federal and state
legislative proposals are periodically introduced or proposed that would affect major changes in the healthcare system, nationally, at the state level or both. Future legislation, regulation or payment policies of Medicare, Medicaid, private health
insurance plans, health maintenance organizations and other third-party payors could adversely affect the demand for our current or future products and our ability to sell our products on a profitable basis. Moreover, healthcare legislation is an
area of extensive and dynamic change, and we cannot predict future legislative changes in the healthcare field or their impact on our industry or our business. Any impairment in our ability to market our products could have a material adverse effect
on our financial condition and results of operation.



We
may not be able to realize the deferred tax asset relating to our tax net operating loss carry forward.



As of June 30, 2005 IRIS has deferred tax assets of approximately $10.3 million resulting from the differences between the financial statement and the tax
bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. There is no assurance that we will be able to generate taxable income in the years that the differences reverse. Also,
should the Company undergo an



26



---

##### Table of Contents

ownership change as defined in Section 382 of the Internal Revenue Code, the Companys NOL generated prior to the ownership change would be subject to
an annual limitation. If this occurs, a valuation allowance may be necessary.



Our success depends largely on sales of laboratory instruments and related sales of consumables and service contracts.



Historically, we derived most of our revenues from the sale of urinalysis instruments. Relatively modest declines in unit
sales or gross margins for this product line could diminish our revenues and profits. In addition, because our installed instruments utilize a large volume of consumables and produce service revenue, any decline in our installed base will diminish
our revenues and profits even further.



We rely on
independent and some single-source suppliers for key components of our instruments. Any delay or disruption in the supply of components may prevent us from selling our products and negatively impact our operations.



Certain of our components are obtained from outside vendors, and the loss or
breakdown of our relationships with these outside vendors could subject us to substantial delays in the delivery of our products to our customers. Furthermore certain key components of our instruments are manufactured by only one supplier. For
example, ARKRAY is the single source supplier for our new line of urine chemistry analyzers and related consumable products and spare parts. Roche Diagnostics is the sole source for our proprietary CHEMSTRIP/IRIStrip urine test strips and related
urine test strip readers, both used in our legacy instruments, the Model 500 and 939 UDx urinalysis workstations. Because these suppliers are the only vendors with which we have a relationship for a particular component, we may be unable to sell
products if one of these suppliers becomes unwilling or unable to deliver components meeting our specifications. Our inability to sell products to meet delivery schedules could have a material adverse effect on our reputation in the industry as well
as our financial condition and results of operation.



One
of our single-source suppliers has terminated its agreement with us.



Roche Diagnostics has exercised its right to terminate its agreements with us relating to the supply of test strips and related urine test strip readers. Roche will continue to supply test strips and replacement
readers to our installed base of legacy workstations for six years after termination of these contracts or 2009. The failure to successfully and timely complete the phase out of their strips and readers with the introduction of our new iQ200
analyzers would have a material adverse affect on our instrument sales and the revenue growth for system supplies and service.



We face intense competition and our failure to compete effectively, particularly against larger, more established companies will cause our business
to suffer.



The healthcare industry is highly
competitive. We compete in this industry based primarily on product performance, service and price. Many of our competitors have substantially greater financial, technical and human resources than we do, and may also have substantially greater
experience in developing products, obtaining regulatory approvals and manufacturing and marketing and distribution. As a result, they may be better able to compete for market share, even in areas in which our products may be superior. Further, our
competitive position could be harmed by the establishment of patent protection by our competitors or other companies. The existing competitors or other companies may succeed in developing technologies and products that are more effective or
affordable than those being developed by us or that would render our technology and products less competitive or obsolete. If we are unable to effectively compete in our market, our financial condition and results of operation will materially
suffer.



Our success depends on our ability to attract,
retain and motivate management and other skilled employees.



Our success depends in significant part upon the continued services of key management and skilled personnel. Competition for qualified personnel is intense and there are a limited number of people with knowledge of, and experience in, our
industry. We do not have employment agreements with most of our key employees nor maintain life insurance polices on them. The loss of key personnel, especially without advance notice, or our inability to hire or retain qualified personnel, could
have a material adverse effect on our



27



---

##### Table of Contents

instrument sales and our ability to maintain our technological edge. We cannot guarantee that we will continue to retain our key management and skilled
personnel, or that we will be able to attract, assimilate and retain other highly qualified personnel in the future.



Defective products may subject us to liability.



Our products are used to gather information for medical decisions and diagnosis. Accordingly, a defect in the design or manufacture of our products, or a
failure of our products to perform for the use that we specify, could have a material adverse effect on our reputation in the industry and subject us to claims of liability arising from inaccurate or allegedly inaccurate test results. Misuse of our
products by a technician that results in inaccurate or allegedly inaccurate test results could similarly subject us to claims of liability. We currently maintain product liability insurance coverage for up to $1.0 million per incident and up to an
aggregate of $2.0 million per year. We also currently maintain a product liability umbrella policy for coverage of claims aggregating to $10.0 million. Although management believes this liability coverage is sufficient protection against future
claims, there can be no assurance of the sufficiency of these policies. Any substantial underinsured loss would have a material adverse effect on our financial condition and results of operation. Furthermore, any impairment of our reputation could
have a material adverse effect on our sales, revenues and prospects for future business. We have not received any indication that our insurance carrier will not renew our product liability insurance at or near current premiums; however, we cannot
guarantee that this will continue to be the case. In addition, any failure to comply with Federal Drug Administration regulations governing manufacturing practices could hamper our ability to defend against product liability lawsuits.



Business interruptions could adversely affect our business.



Products for Iris Diagnostics and StatSpin are
manufactured in a single facility for each division and are vulnerable to interruption in the event of war, terrorism, fire, earthquake, power loss, floods, telecommunications failure and other events beyond our control. If our facilities were
significantly damaged or destroyed by any cause, we would experience delays in locating a new facility and equipment and qualifying the new facility with the FDA. Our results would suffer. In addition, we may not carry adequate business interruption
insurance to compensate us for losses that may occur and any losses or damages incurred by us could be substantial.



If we are unable to manage our growth, our results could suffer.



We have been experiencing significant growth in the scope of our operations. This growth has placed significant demands on
our management as well as operational resources. In order to achieve our business objectives, we anticipate that we will need to continue to grow. If this growth occurs, it will continue to place additional significant demands on our management and
our operational resources, and will require that we continue to develop and improve our operational, financial and other internal controls both in the U.S. and internationally. In particular, our growth rate has increased, if it continues, will
increase the challenges in implementing appropriate control systems, expanding our sales and marketing infrastructure capabilities, providing adequate training and supervision to maintain high quality standards, and preserving our cultural values.
The main challenge associated with our growth has been cash flow management. Our inability to scale our business appropriately or otherwise adopt to growth, could cause our business, financial condition and results of operations to suffer.



Our quarterly sales and operating results may fluctuate
in future periods, and if we fail to meet expectations the price of our common stock may decline.



Our quarterly sales and operating results have fluctuated significantly in the past and are likely to do so in the future due to a number of factors, many
of which are not within our control. If our quarterly sales or operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Factors that might cause quarterly
fluctuations in our sales and operating results include the following:



| |  |  | variation in demand for our products, including seasonality;
| | - |  | ------------------------------------------------------------



| |  |  | our ability to develop, introduce, market and gain market acceptance of new products and product enhancements in a timely manner;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to manage inventories, accounts receivable and cash flows;
| | - |  | ----------------------------------------------------------------------



28



---

##### Table of Contents

| |  |  | our ability to control costs;
| | - |  | -----------------------------



| |  |  | the size, timing, rescheduling or cancellation of orders from consumers and distributors; AND
| | - |  | ---------------------------------------------------------------------------------------------



| |  |  | our ability to forecast future sales and operating results and subsequently attain them.
| | - |  | ----------------------------------------------------------------------------------------



The amount of expenses we incur depends, in part, on our expectations regarding future sales. In particular, we expect to
continue incurring substantial expenses relating to the marketing and promotion of our products. Since many of our costs are fixed in the short term, if we have a shortfall in sales, we may be unable to reduce expenses quickly enough to avoid
losses. If this occurs, we will not be profitable. Accordingly, you should not rely on quarter-to-quarter comparisons of our operating results as an indication of our future performance.



We depend on independent distributors to sell our products in international markets.



We sell our products in international markets through independent
distributors. These distributors may not command the necessary resources to effectively market and sell our products. If a distributor fails to meet annual sales goals, it may be difficult and costly to locate an acceptable substitute distributor.
If a change in our distributors becomes necessary, we may experience increased costs, as well as substantial disruption and a resulting loss of sales.



Our sales in international markets are subject to a variety of laws and political and economic risks that may adversely impact our sales and results
of operations in certain regions.



Our ability to
capitalize on growth in new international markets and to maintain the current level of operations in our existing international markets is subject to risks associated with international sales operations. These include:



| |  |  | changes in currency exchange rates which impact the price to international consumers;
| | - |  | -------------------------------------------------------------------------------------



| |  |  | the burdens of complying with a variety of foreign laws and regulations;
| | - |  | ------------------------------------------------------------------------



| |  |  | unexpected changes in regulatory requirements; and
| | - |  | --------------------------------------------------



| |  |  | the difficulties associated with promoting products in unfamiliar cultures.
| | - |  | ---------------------------------------------------------------------------



We are also subject to general, political, economic and regulatory risks in connection with our international sales operations, including:



| |  |  | political instability;
| | - |  | ----------------------



| |  |  | changes in diplomatic and trade relationships;
| | - |  | ----------------------------------------------



| |  |  | general economic fluctuations in specific countries or markets; and
| | - |  | -------------------------------------------------------------------



| |  |  | changes in regulatory schemes.
| | - |  | ------------------------------



Any of the abovementioned factors could adversely affect our sales and results of operations in international markets.



We are subject to currency fluctuations.



We are exposed to certain foreign currency risks in the importation of goods
from Japan The new line of urine chemistry analyzers, two assemblies for our iQ200 platform and related consumables strips and spare parts are sourced from ARKRAY, a supplier located in Kyoto, Japan. Our purchases from this supplier are denominated
in Japanese Yen. These components represent a significant portion of our material costs. Fluctuations in the U.S. Dollar/ Japanese Yen exchange rate could result in increased costs for our key components. Any increases would reduce our gross margins
and would be likely to result in a material adverse effect on our revenues and financial condition. Similarly, we are also exposed to currency fluctuations with respect to the exportation of our products. All of our sales are denominated in U.S.
Dollars. Accordingly, any fluctuation in the exchange rate between the U.S. Dollar and the currency of the country with which we are exporting products could also affect our ability to sell internationally.



29



---

##### Table of Contents

Risks Related to Ownership of Our Common Stock



Anti-takeover provisions of Delaware law could delay or prevent an acquisition of our Company.



We are subject to the anti-takeover provisions of Section 203 of the
Delaware General Corporation Law, which regulates corporate acquisitions. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging
others from making tender offers for our common stock or preventing changes in our management.



|Item 3. | Quantitative and Qualitative Disclosures About Market Risk
|------- | ----------------------------------------------------------



Our business is exposed to various market risks relating to fluctuations in interest rates and foreign currency exchange
rates. Market risk is the potential loss arising from adverse changes in market rates and prices, such as interest rates and foreign currency exchange rates. We do not invest in derivatives or other financial instruments for trading or speculative
purposes.



Interest Rates



At June 30, 2005, we did not have any outstanding indebtedness subject to
interest rate fluctuations. All of our cash equivalents are held in United States bank accounts and we do not believe we have significant market risk exposure with regard to our investments.



Foreign Currencies



We are subject to some currency risk on a portion of our licensing revenues
for product sales in Japan, as well as from purchases of products from our Japanese manufacturer of the AX-4280. The licensing portion of our revenues is calculated quarterly based on sales results in Japanese Yen and subsequently converted into
United States dollars at the then current exchange rate. Our purchases of products from our Japanese supplier are negotiated annually and may be affected by changing foreign currency rates. Additionally, currency fluctuations can increase the price
of our products to foreign customers which can adversely impact the level of our export sales from time to time.



|Item 4. | Controls and Procedures
|------- | -----------------------



Evaluation of Disclosure Controls and Procedures



We maintain disclosure controls and procedures, as defined by paragraph (e) of Exchange Act Rules 13a-15 or 15d-15, designed to ensure that we are able
to collect the information we are required to disclose in the reports we file with the SEC and to approve, summarize and disclose this information within the time periods specified in the rules of the SEC. Our Chief Executive Officer and Chief
Financial Officer are responsible for establishing and maintaining these procedures, and, as required by the rules of the SEC, evaluate their effectiveness. Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of
our disclosure controls and procedures as of June 30, 2005, the end of the period covered by this report, and based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
are effective.



Changes in Internal Controls over
Financial Reporting



We maintain a system of internal
controls designed to provide reasonable assurance that transactions are executed in accordance with managements general or specific authorization; transactions are recorded as necessary (1) to permit preparation of financial statements in
conformity with generally accepted accounting principles, (2) to maintain accountability for assets, and (3) to ensure that access to assets is permitted only in accordance with managements general or specific authorization; and the recorded
accountability for access is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.



30



---

##### Table of Contents

Since the date of the most recent evaluation of our internal controls over financing reporting by the
Chief Executive Officer and Chief Financial Officer, there have been no significant changes in such controls or in other factors that could have significantly affected those controls, including any corrective actions with regard to significant
deficiencies and material weaknesses.



Limitations on the
Effectiveness of Controls



The Company maintains a system of
internal accounting controls to provide reasonable assurance that assets are safeguarded and that transactions are executed in accordance with managements authorization and recorded properly to permit the preparation of financial statements in
accordance with accounting principles generally accepted in the United States. However, the Companys management, including the CEO and CFO, does not expect that the Companys disclosure controls or internal controls will prevent all
errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact
that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control
issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake.
Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions
about the likelihood of future events, and there can be no absolute assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in
conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.



31



---

##### Table of Contents

PART II

OTHER INFORMATION



|Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds
|------- | -----------------------------------------------------------



From April 1, 2005 through June 30, 2005 the Registrant has issued and sold the following securities:



| | 1. | In April 2005, we issued to The Pinnacle Fund, LP, 71,424 shares of common stock upon the cashless exercise of warrants to purchase 150,000 shares of common stock at an exercise
price of $7.80 per share.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | In May 2005, we issued to Mr. Zubin Mory, 275 shares of common stock upon the cashless exercise to purchase 500 shares of common stock at an exercise price of $7.80 per share.
| | -- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 3. | In May 2005, we issued to Mr. Frank K. Colen, 11,080 shares of common stock upon the cashless exercise of warrants to purchase 20,000 shares of common stock at an exercise price of
$7.80 per share.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 4. | In May 2005, we issued to Mr. Corey Dorzek, 554 shares of common stock upon the cashless exercise of warrants to purchase 1,000 shares of common stock at an exercise price of $7.80
per share.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 5. | In May 2005, we issued to Mr. Henry Williams, 4,585 shares of common stock upon the cashless exercise of warrants to purchase 8,275 shares of common stock at an exercise price of
$7.80 per share.
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 6. | In May 2005, we issued to the Oppenheimer & Co., Inc., 31,716 shares of common stock upon the cashless exercise of warrants to purchase 58,175 shares of common stock at an
exercise price of $7.80 per share.
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 7. | In June 2005, we issued to Mr. Chris Hager, 3,235 shares of common stock upon the cashless exercise of warrants to purchase 5,600 shares of common stock at an exercise price of
$7.80 per share.
| | -- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 8. | In June 2005, we issued to Ms. Yvonne Briggs, 6,510 shares of common stock upon the cashless exercise of warrants to purchase 11,000 shares of common stock at an exercise price of
$7.80 per share.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 9. | In June 2005, we issued to Mr. Andrew Kaminsky, 592 shares of common stock upon the cashless exercise of warrants to purchase 1,000 shares of common stock at an exercise price of
$7.80 per share.
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 10. | In June 2005, we issued to Mr. Robert Powers, 3,484 shares of common stock upon the cashless exercise of warrants to purchase 6,125 shares of common stock at an exercise price of
$7.80 per share.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



The issuance and sales of these securities was
made in reliance on Section 4(2) and/or Section 3(a)(9) of the Securities Act and/or Regulation D promulgated under the Securities Act. These sales were made without general solicitation or advertising. Each purchaser was a sophisticated investor
with access to all relevant information necessary to evaluate the investment and represented to the Registrant that the shares were being acquired for investment.



32



---

##### Table of Contents

|Item 6. | Exhibits
|------- | --------



|              |  |                                                                                                        |  |                   
|------------- |  | ------------------------------------------------------------------------------------------------------ |  | ------------------
|ExhibitNumber |  | Description                                                                                            |  | Reference Document
|              |  |                                                                                                       
|31.1          |  | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer     |  | *                 
|              |  |                                                                                                       
|31.2          |  | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Principal Financial Officer |  | *                 
|              |  |                                                                                                       
|32.1          |  | Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer     |  | *                 
|              |  |                                                                                                       
|32.2          |  | Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Principal Financial Officer |  | *                 



|* | filed herewith
|- | --------------



33



---

##### Table of Contents

SIGNATURE



Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



Date: August 12, 2005



IRIS INTERNATIONAL, INC.By:

/s/ Martin G. ParavatoMartin G. ParavatoChief Financial Officer




34